Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma

被引:1
|
作者
Wei, Xiaomu [1 ,2 ]
Calvo-Vidal, M. Nieves [1 ]
Chen, Siwei [2 ]
Wu, Gang [3 ]
Revuelta, Maria V. [1 ]
Sun, Jian [1 ]
Zhang, Jinghui [3 ]
Walsh, Michael F. [4 ]
Nichols, Kim E. [3 ]
Joseph, Vijai [4 ]
Snyder, Carrie [5 ]
Vachon, Celine M. [6 ]
Mckay, James D. [7 ]
Wang, Shu-Ping [8 ]
Jayabalan, David S. [1 ]
Jacobs, Lauren M. [4 ]
Becirovic, Dina [5 ]
Waller, Rosalie G. [9 ]
Artomov, Mykyta [10 ]
Viale, Agnes [4 ]
Patel, Jayeshkumar [1 ]
Phillip, Jude [1 ]
Chen-Kiang, Selina [1 ]
Curtin, Karen [9 ]
Salama, Mohamed [9 ]
Atanackovic, Djordje [9 ]
Niesvizky, Ruben [1 ]
Landgren, Ola [4 ]
Slager, Susan L. [6 ]
Godley, Lucy A. [11 ]
Churpek, Jane [11 ]
Garber, Judy E. [12 ]
Anderson, Kenneth C. [12 ]
Daly, Mark J. [10 ]
Roeder, Robert G. [8 ]
Dumontet, Charles [7 ]
Lynch, Henry T. [5 ]
Mullighan, Charles G. [3 ]
Camp, Nicola J. [9 ]
Offit, Kenneth [4 ]
Klein, Robert J. [13 ]
Yu, Haiyuan [2 ]
Cerchietti, Leandro [1 ]
Lipkin, Steven M. [1 ]
机构
[1] Weill Cornell Med, Dept Med, 413 East 69th St,Belfer Rm 702, New York, NY 10021 USA
[2] Cornell Univ, Weill Inst Cell & Mol Biol, Dept Biol Stat & Computat Biol, Ithaca, NY USA
[3] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA
[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[5] Creighton Univ, Omaha, NE 68178 USA
[6] Mayo Clin, Rochester, MN USA
[7] Canc Res Ctr Lyon, Lyon, France
[8] Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA
[9] Univ Utah, Salt Lake City, UT USA
[10] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA
[11] Univ Chicago, Chicago, IL 60637 USA
[12] Dana Farber Canc Inst, Boston, MA 02115 USA
[13] Icahn Sch Med, New York, NY USA
关键词
DRUG-RESISTANCE; PROLIFERATION; LSD1; MYC; HETEROGENEITY; PROGRESSION; VARIANTS; REVEALS; PATHWAY; BURDEN;
D O I
10.1158/0008-5472.CAN-17-1900
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Given the frequent and largely incurable occurrence of multiple myeloma, identification of germline genetic mutations that predispose cells to multiple myeloma may provide insight into disease etiology and the developmental mechanisms of its cell of origin, the plasma cell (PC). Here, we identified familial and early-onset multiple myeloma kindreds with truncating mutations in lysine-specific demethylase 1 (1,SDI/KDM1A), an epigenetic transcriptional repressor that primarily demethylates histone H3 on lysine 4 and regulates hematopoietic stem cell self-renewal. In addition, we found higher rates of germline truncating and predicted deleterious missense KDM1A mutations in patients with multiple myeloma unselected for family history compared with controls. Both monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma cells have significantly lower KDM1A transcript levels compared with normal PCs. Transcriptome analysis of multiple myeloma cells from KDM1A mutation carriers shows enrichment of pathways and MYC target genes previously associated with myeloma pathogenesis. In mice, antigen challenge followed by pharmacologic inhibition of KDM1A promoted PC expansion, enhanced secondary immune response, elicited appearance of serum paraprotein, and mediated upregulation of MYC transcriptional targets. These changes are consistent with the development of MGUS. Collectively, our findings show that KDM1A is the first autosomal-dominant multiple myeloma germline predisposition gene providing new insights into its mechanistic roles as a tumor suppressor during post-germinal center B-cell differentiation. Significance: KDM1A is the first germline autosomal dominant predisposition gene identified in multiple myeloma and provides new insights into multiple myeloma etiology and the mechanistic role of KDM1A as a tumor suppressor during post-germinal center B cell differentiation. (C) 2018 AACR.
引用
收藏
页码:2747 / 2759
页数:13
相关论文
共 50 条
  • [41] Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma
    Alejo, Salvador
    Palacios, Bridgitte E.
    Venkata, Prabhakar Pitta
    He, Yi
    Li, Wenjing
    Johnson, Jessica D.
    Chen, Yihong
    Jayamohan, Sridharan
    Pratap, Uday P.
    Clarke, Kyra
    Zou, Yi
    Lv, Yingli
    Weldon, Korri
    Viswanadhapalli, Suryavathi
    Lai, Zhao
    Ye, Zhenqing
    Chen, Yidong
    Gilbert, Andrea R.
    Suzuki, Takayoshi
    Tekmal, Rajeshwar R.
    Zhao, Weixing
    Zheng, Siyuan
    Vadlamudi, Ratna K.
    Brenner, Andrew J.
    Sareddy, Gangadhara R.
    NEURO-ONCOLOGY, 2023, 25 (07) : 1249 - 1261
  • [42] Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments efficacy of temozolomide in glioblastoma
    Alejo, Salvador
    Palacios, Bridgitte
    Venkata, Prabhakar Pitta
    Yi, He
    Li, Wenjing
    Johnson, Jessica
    Jayamohan, Sridharan
    Zhao, Weixing
    Zheng, Siyuan
    Suzuki, Takayoshi
    Tekmal, Rajeshwar R.
    Brenner, Andrew
    Vadlamudi, Ratna K.
    Sareddy, Gangadhara R.
    CANCER RESEARCH, 2023, 83 (07)
  • [43] Inhibition of lysine-specific histone demethylase LSD1 suppresses melanoma growth
    Lian, Christine Guo
    Fang, Rui
    Zhan, Qian
    Ma, Jie
    Lee, Chung-Wei
    Frank, Markus H.
    Shi, Yujiang Geno
    Murphy, George F.
    FASEB JOURNAL, 2013, 27
  • [44] Regulation of Lipogenic Gene Expression by Lysine-specific Histone Demethylase-1 (LSD1)
    Abdulla, Arian
    Zhang, Yi
    Hsu, Fu-Ning
    Xiaoli, Alus M.
    Zhao, Xiaoping
    Yang, Ellen S. T.
    Ji, Jun-Yuan
    Yang, Fajun
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (43) : 29937 - 29947
  • [45] Lysine-Specific Demethylase 1 (LSD1) Inhibitors as Potential Treatment for Different Types of Cancers
    Abdel-Magid, Ahmed F.
    ACS MEDICINAL CHEMISTRY LETTERS, 2017, 8 (11): : 1134 - 1135
  • [46] A requirement for Lysine-specific histone demethylase 1A (Lsd1) for T cell development
    Stamos, Daniel
    Li, Liqi
    Rosenfeld, Michael
    Love, Paul E.
    JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
  • [47] Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A)
    Li, Zhonghua
    Ding, Lina
    Li, Zhongrui
    Wang, Zhizheng
    Suo, Fengzhi
    Shen, Dandan
    Zhao, Taoqian
    Sun, Xudong
    Wang, Junwei
    Liu, Ying
    Ma, Liying
    Zhao, Bing
    Geng, Pengfei
    Yu, Bin
    Zheng, Yichao
    Liu, Hongmin
    ACTA PHARMACEUTICA SINICA B, 2019, 9 (04) : 794 - 808
  • [48] Activation of HIV Transcription by the Viral Tat Protein Requires a Demethylation Step Mediated by Lysine-specific Demethylase 1 (LSD1/KDM1)
    Sakane, Naoki
    Kwon, Hye-Sook
    Pagans, Sara
    Kaehlcke, Katrin
    Mizusawa, Yasuhiro
    Kamada, Masafumi
    Lassen, Kara G.
    Chan, Jonathan
    Greene, Warner C.
    Schnoelzer, Martina
    Ott, Melanie
    PLOS PATHOGENS, 2011, 7 (08)
  • [49] Downregulation of lysine-specific histone demethylase 1A (KDM1A/LSD1) in medial prefrontal cortex facilitates chronic stress-induced pain and emotional dysfunction in female mice
    Wei, Si-qi
    Wei, Jian-Xiong
    Zhao, Shijie
    Cao, Dong-Yuan
    Liang, Lingli
    NEUROPHARMACOLOGY, 2024, 254
  • [50] Impact Of Ovariectomy On Aldosterone And Blood Pressure In Lysine-Specific Demethylase 1 (LSD1) Deficient Mice
    Stanton, Ana Maria
    Aljaibeji, Hayat
    Gholami, Shadi K.
    Parksook, Wasita
    Ding, Miao
    Gomez, Dulce H.
    Romero, Jose R.
    Pojoga, Luminita H.
    Williams, Gordon H.
    Adler, Gail K.
    HYPERTENSION, 2023, 80